FGFR a promising druggable target in cancer: Molecular biology and new drugs

Rut Porta(Catalan Institute for Water Research), Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jose Ferri(Antwerp University Hospital), Aung Naing(The University of Texas MD Anderson Cancer Center), Roberto Borea(Antwerp University Hospital), Rafael Sirera(Antwerp University Hospital), Nele Van Der Steen(University of Antwerp), Pablo Reclusa(University of Antwerp), António Araújo, Andreia Coelho(Antwerp University Hospital), Shahanavaj Khan(King Saud University), Tindara Franchina(University of Messina), David S. Hong(The University of Texas MD Anderson Cancer Center), Peter A. van Dam(GZA Ziekenhuizen Campus Sint-Augustinus)
Critical Reviews in Oncology/Hematology
March 23, 2017
10.1016/j.critrevonc.2017.02.018
Cited by 203

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661